A decreased ratio between serum levels of the antagonistic angiopoietins 1 and 2 indicates tumour progression of malignant melanoma

Archives of Dermatological Research

Volumn 304, Issue 5, 2012, Pages 397-400

  Gardizi, Masyar ^a   Kurschat, Christine ^a   Riese, Anna ^a   Hahn, Moritz ^a   Krieg, Thomas ^a   Mauch, Cornelia ^a   Kurschat, Peter ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Angiogenesis; Angiopoietin; Malignant melanoma; S100B; Tumour marker

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; PROTEIN S100B; TIE RECEPTOR; VASCULOTROPIN;

ANGIOGENESIS; AREA UNDER THE CURVE; ARTICLE; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISTANT METASTASIS; ENDOTHELIUM CELL; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MELANOMA; MICROMETASTASIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TUMOR GROWTH;

ANGIOPOIETIN-1; ANGIOPOIETINS; DISEASE PROGRESSION; HUMANS; MELANOMA; NEOVASCULARIZATION, PATHOLOGIC; NERVE GROWTH FACTORS; RECEPTOR, TIE-2; S100 PROTEINS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84864750133     PISSN: 03403696     EISSN: 1432069X     Source Type: Journal    
DOI: 10.1007/s00403-012-1228-2     Document Type: Article

References (20)

1. Acland K, Evans AV, Abraha H, Healy CM, Roblin P, Calonje E, Orchard G, Higgins E, Sherwood R, Russell-Jones R (2002) Serum S100 concentrations are not useful in predicting micrometastatic disease in cutaneous malignant melanoma. Br J Dermatol 146(5):832-835
2. Augustin HG, Koh GY, Thurston G, Alitalo K (2009) Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 10(3):165-177
3. Bach F, Uddin FJ, Burke D (2007) Angiopoietins in malignancy. Eur J Surg Oncol 33(1):7-15
4. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sober AJ, Sondak VK (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27(36):6199-6206
5. Deichmann M, Benner A, Bock M, Jackel A, Uhl K, Waldmann V, Naher H (1999) S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol 17(6):1891-1896
6. Fukuhara S, Sako K, Noda K, Zhang J, Minami M, Mochizuki N (2010) Angiopoietin-1/Tie2 receptor signaling in vascular quiescence and angiogenesis. Histol Histopathol 25(3):387-396
7. Garbe C, Leiter U, Ellwanger U, Blaheta HJ, Meier F, Rassner G, Schittek B (2003) Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/ MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients. Cancer 97(7):1737-1745
8. Helfrich I, Edler L, Sucker A, Thomas M, Christian S, Schadendorf D, Augustin HG (2009) Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma. Clin Cancer Res 15(4):1384-1392
9. Huang H, Bhat A, Woodnutt G, Lappe R (2010) Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer 10(8): 575-585
10. Kurschat P, Eming S, Nashan D, Krieg T, Mauch C (2007) Early increase in serum levels of the angiogenesis-inhibitor endostatin and of basic fibroblast growth factor in melanoma patients during disease progression. Br J Dermatol 156(4):653-658
11. Lobov IB, Brooks PC, Lang RA (2002) Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci USA 99(17): 11205-11210
12. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, Daly TJ, Davis S, Sato TN, Yancopoulos GD (1997) Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277(5322):55-60
13. Park JH, Park KJ, Kim YS, Sheen SS, Lee KS, Lee HN, Oh YJ, Hwang SC (2007) Serum angiopoietin-2 as a clinical marker for lung cancer. Chest 132(1):200-206
14. Pichiule P, Chavez JC, LaManna JC (2004) Hypoxic regulation of angiopoietin-2 expression in endothelial cells. J Biol Chem 279(13):12171-12180
15. Shim WS, Ho IA, Wong PE (2007) Angiopoietin: a TIE(d) balance in tumor angiogenesis. Mol Cancer Res 5(7):655-665
16. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN, Yancopoulos GD (1996) Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87(7):1171-1180
17. Tait CR, Jones PF (2004) Angiopoietins in tumours: the angiogenic switch. J Pathol 204(1):1-10
18. Thomas M, Augustin HG (2009) The role of the angiopoietins in vascular morphogenesis. Angiogenesis 12(2):125-137
19. Ugurel S, Rappl G, Tilgen W, Reinhold U (2001) Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 19(2):577-583
20. Utikal J, Schadendorf D, Ugurel S (2007) Serologic and immunohistochemical prognostic biomarkers of cutaneous malignancies. Arch Dermatol Res 298(10):469-477